Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
Authors
Keywords
-
Journal
Cancers
Volume 9, Issue 12, Pages 15
Publisher
MDPI AG
Online
2017-01-28
DOI
10.3390/cancers9020015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
- (2016) A. Balar et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
- (2016) Arjun Vasant Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.
- (2016) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.
- (2016) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. ONCOLOGIST
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
- (2014) Evan Gomes-Giacoia et al. PLoS One
- Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies
- (2011) M. N. Fishman et al. CLINICAL CANCER RESEARCH
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
- (2010) Guru Sonpavde et al. LANCET ONCOLOGY
- A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder
- (2008) Atreya Dash et al. CANCER
- Targeting activity of a TCR/IL-2 fusion protein against established tumors
- (2008) Jinghai Wen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started